[Intravitreal ranibizumab for age-related macular degeneration].

INTRODUCTION

Ranibizumab has improved visual prognosis for patients with age-related macula degeneration (ARMD) complicated with choroidal neovascularisation. We evaluated the results of all our patients within a two-year period.

MATERIAL AND

METHODS

A total of 647 eyes have so far been treated. In all 2,735 injections have been performed.

RESULTS

Ranibizumab initially increased significantly the best corrected visual acuity from 0.29 to 0.35 (p < 0.001), but after six and 12 months visual acuity stabilized (p = 0.1). We found a positive correlation between initial visual acuity and final visual acuity (p < 0.001). There was a negative correlation between age and final visual acuity (p < 0.001). Complications were rare: one got cataract, we observed a retinal detachment and one choroidal detachment. Other complications were rare and mild.

CONCLUSION

Ranibizumab improves visual prognosis in exudative ARMD. Intravitreal injections are safe and complications are rare.